INCY Stock Risk & Deep Value Analysis
Incyte Corp
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About INCY Stock
We analyzed Incyte Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INCY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is INCY Stock?
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for INCY?
- ⚠
Clinical trial failures or unexpected safety signals for pipeline drugs
- ⚠
Increased generic competition for Jakafi post-patent expiry (further out, but always a factor)
- ⚠
Regulatory delays or rejections for new drug applications or label expansions
- ⚠
Pricing pressure from payers or government healthcare reforms
Unlock INCY Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Incyte Corp (INCY) Do?
Market Cap
$20.86B
Sector
Healthcare
Industry
Biotechnology
Employees
2,617
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Visit Incyte Corp WebsiteIs INCY Stock Undervalued?
Unlock the full AI analysis for INCY
Get the complete DVR score, risk analysis, and more
Is INCY Financially Healthy?
P/E Ratio
18.01
Does INCY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
Incyte's moat is primarily driven by its patented blockbuster drugs like Jakafi and newer approvals like Opzelura. While these offer significant protection, the eventual patent expiry and emerging competitive landscape in oncology and dermatology represent ongoing threats.
Moat Erosion Risks
- •Patent cliff risks on flagship products
- •Emergence of superior or biosimilar competitors
- •Regulatory changes impacting drug approval pathways
INCY Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive INCY Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Call (Estimated late February/early March 2026)
- •Data readouts from ongoing Phase 2 trials for select oncology candidates (H1 2026)
- •Potential label expansion application for Opzelura in new dermatological indications (Q2 2026)
Medium-Term (6-18 months)
- •Initiation of pivotal Phase 3 trials for promising pipeline assets (Late 2026 - Early 2027)
- •Geographic expansion of key products like Opzelura into new markets (2027)
- •Strategic partnerships or bolt-on acquisitions to bolster pipeline (2027-2028)
Long-Term (18+ months)
- •Evolution of the oncology and inflammatory disease treatment landscape, favoring targeted therapies (2028+)
- •Successful development and commercialization of next-generation oncology agents (2028+)
- •Market leadership in specific niche therapeutic areas within dermatology/hematology (2028+)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for INCY?
- ✓
Acceleration in Opzelura sales growth and market penetration
- ✓
Positive Phase 3 clinical trial data readouts for key pipeline assets
- ✓
Sustainable double-digit revenue growth guidance for core products
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INCY (Incyte Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
